CFDA Halts Imports from Swiss Manufacturer

The China Food and Drug Administration has blocked imports of Panfosu, a bacterial lysate capsule, from Switzerland-based OM Pharma.

CFDA inspectors found the facility did not meet GMP standards in manufacturing the product.

Based on the inspection report, the CFDA revoked OM Pharma’s marketing clearance for the drug.

OM Pharma, a subsidiary of the Galenica Group, is a biotech firm specialized in products for infectious diseases.